Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic Acid Extension in Children with Severe Osteogenesis Imperfecta
NCT00131118Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2004
- Primary completion
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of zoledronic acid in osteogenesis imperfecta (OI) (2 arms), sponsored by Novartis. Primary endpoint: Long-term safety at 12 months. Started Jul 2004; status: completed.
02
Drugs
zoledronic acid
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on NCT00131118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00131118.